Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8528869 | 1.00 | KDM4E (0.48) | KDM4EPDE4ALMNAL3MBTL1TDP1 | |
| SCHEMBL10299846 | 1.00 | KDM4E (0.48) | KDM4EPDE4ALMNAL3MBTL1TDP1 | |
| Hydrochloric Acid SCHEMBL8528184 | 0.98 | KDM4E (0.47) | KDM4EPDE4ALMNAL3MBTL1TDP1 | |
| SCHEMBL25262519 | 0.82 | PDE4A (0.42) | KDM4EPDE4ALMNAL3MBTL1TDP1 | |
| SCHEMBL10299778 | 0.80 | PDE4A (0.41) | KDM4EPDE4ALMNAL3MBTL1TDP1 | |
| SCHEMBL11350754 | 0.80 | PDE4A (0.41) | KDM4EPDE4ALMNAL3MBTL1TDP1 | |
| SCHEMBL8532266 | 0.80 | PDE4A (0.41) | KDM4EPDE4ALMNAL3MBTL1TDP1 | |
| SCHEMBL16201531 | 0.80 | PDE4A (0.41) | KDM4EPDE4ALMNAL3MBTL1TDP1 | |
| SCHEMBL11414474 | 0.80 | PDE4A (0.41) | KDM4EPDE4ALMNAL3MBTL1TDP1 | |
| SCHEMBL8829389 | 0.79 | PDE4A (0.43) | KDM4EPDE4ALMNAL3MBTL1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2515850-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CEFDINIR AS AN ACTIVE AGENT | BILGIC MAHMUT (TR) | 2016-06-29 | — | — | EP | claimed |
| EP-2780748-B1 | A SILICONE HYDROGEL LENS WITH A CROSSLINKED HYDROPHILIC COATING | NOVARTIS AG (CH) | 2016-01-13 | — | — | EP | claimed |
| EP-2515860-B1 | IMPROVED PHARMACEUTICAL COMPOSITIONS COMPRISING CEFDINIR | BILGIC MAHMUT (TR) | 2015-07-29 | — | — | EP | claimed |
| EP-2718751-B1 | SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES | NOVARTIS AG (CH) | 2015-07-22 | — | — | EP | claimed |
| EP-2516448-B1 | AMINE SALTS OF CEFDINIR | BILGIC MAHMUT (TR) | 2015-04-15 | — | — | EP | claimed |
| EP-2780748-A1 | A SILICONE HYDROGEL LENS WITH A CROSSLINKED HYDROPHILIC COATING | Novartis AG (CH) | 2014-09-24 | — | — | EP | claimed |
| EP-2718751-A1 | SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES | Novartis AG (CH) | 2014-04-16 | — | — | EP | claimed |
| US-20140079647-A1 | CEFDINIR AND CEFIXIME FORMULATIONS AND USES THEREOF | BILGIC MAHMUT (TR) | 2014-03-20 | — | — | US | claimed |
| US-8614315-B2 | Cefdinir and cefixime formulations and uses thereof | BILGIC MAHMUT (TR) | 2013-12-24 | — | — | US | claimed |
| WO-2013074535-A1 | A SILICONE HYDROGEL LENS WITH A CROSSLINKED HYDROPHILIC COATING | NOVARTIS AG (CH) | 2013-05-23 | — | — | WO | claimed |
| US-20130017156-A1 | CEFDINIR AND CEFIXIME FORMULATIONS AND USES THEREOF | BILGIC MAHMUT (TR) | 2013-01-17 | — | — | US | claimed |
| WO-2012170603-A1 | SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES | NOVARTIS AG (CH) | 2012-12-13 | — | — | WO | claimed |
| EP-4720728-A1 | COATED SILICONE HYDROGEL CONTACT LENSES AND METHOD FOR MAKING THE SAME | Alcon Inc. (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4707877-A2 | METHOD FOR PRODUCING SILICON HYDROGEL CONTACT LENSES WITH CROSSLINKED HYDROPHILIC COATINGS THEREON | Alcon Inc. (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260042268-A1 | SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES | ALCON INC (CH) | 2026-02-12 | — | — | US | disclosed |
| US-20260042269-A1 | SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES | ALCON INC (CH) | 2026-02-12 | — | — | US | disclosed |
| US-5747468-A | Cationic unsaturated saccharides and polymers prepared therefrom, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-05-05 | — | — | US | disclosed |
| US-4307072-A | X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1981-12-22 | — | — | US | disclosed |
| US-4224440-A | NON-IONIC X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1980-09-23 | — | — | US | disclosed |
| US-4109081-A | X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042269-A1 | SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES | CRYZ, STRA6, PHOSPHO1 | KDM4E 1450/4885PDE4A 2929/4885LMNA 214/4885 |
| US-20140079647-A1 | CEFDINIR AND CEFIXIME FORMULATIONS AND USES THEREOF | C1R, CFD, CSF3R | KDM4E 2705/4885PDE4A 495/4885LMNA 3993/4885 |
| US-20130017156-A1 | CEFDINIR AND CEFIXIME FORMULATIONS AND USES THEREOF | C1R, CFD, CSF3R | KDM4E 2705/4885PDE4A 495/4885LMNA 3993/4885 |
| US-20260042268-A1 | SILICONE HYDROGEL LENSES WITH WATER-RICH SURFACES | STRA6, CRYZ, SMCHD1 | KDM4E 1841/4885PDE4A 3999/4885LMNA 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.